Table 3.

Treatment related adverse events occurring in >10% of patients (N=19)

	Any Grade	Grade ≥ 3
Any	16 (84%)	9 (47%)
Serious	6 (32%)	6 (32%)
Led to Discontinuation	1 (5%)	1 (5%)
Lead to Death	1 (5%)	1 (5%)
Fatigue	6 (32%)	0 (0%)
Anemia	5 (26%)	1 (5%)
Anorexia	5 (26%)	0 (0%)
Aspartate aminotransferase increased	4 (21%)	2 (11%)
Diarrhea	4 (21%)	1 (5%)
Nausea	3 (15%)	1 (5%)
Alkaline phosphatase increased	3 (15%)	0 (0%)
Hypothyroidism	3 (15%)	0 (0%)
Rash maculo-papular	3 (15%)	0 (0%)
Alanine aminotransferase increased	2 (11%)	1 (5%)
Hypercalcemia	2 (11%)	1 (5%)
Adrenal insufficiency	2 (11%)	0 (0%)
Arthralgia	2 (11%)	0 (0%)
Constipation	2 (11%)	0 (0%)
Hyperglycemia	2 (11%)	0 (0%)
Hyperthyroidism	2 (11%)	0 (0%)
Lymphocyte count decreased	2 (11%)	0 (0%)
Myalgia	2 (11%)	0 (0%)
Pruritus	2 (11%)	0 (0%)
Immune-mediated	12 (63%)	4 (21%)
Aspartate aminotransferase increased	4 (21%)	2 (11%)
Diarrhea	4 (21%)	1 (5%)
Hypothyroidism	3 (16%)	0 (0%)
Rash maculo-papular	3 (16%)	0 (0%)
Alanine aminotransferase increased	2 (11%)	1 (5%)
Adrenal insufficiency	2 (11%)	0 (0%)
Arthralgia	2 (11%)	0 (0%)
Hyperthyroidism	2 (11%)	0 (0%)
Pruritus	2 (11%)	0 (0%)
Blood bilirubin increased	1 (5%)	1 (5%)
Encephalopathy	1 (5%)	1 (5%)
Lipase increased	1 (5%)	0 (0%)
Pneumonitis	1 (5%)	0 (0%)
Serum amylase increased	1 (5%)	0 (0%)